TABLE 2

Changes in OGTT-derived measures of β-cell function (insulinogenic index) and insulin sensitivity (1/fasting insulin) for the full cohort from baseline to 0.5 years and rates of change among means from 0.5 to 4 years based on a longitudinal model adjusted for baseline factors

VariableRosiglitazoneMetforminGlyburideP value
Rosiglitazone vs. metforminRosiglitazone vs. glyburide
Insulinogenic index (pmol/L per mmol/L)
 n1,1251,1241,060
 Mean %change from 0 to 0.5 years0.0 (−3.9, 4.1)2.5 (−1.5, 6.7)6.6 (2.3, 11.1)0.38260.0249
 Rate of change from 0.5 to 4 years (% per year)−6.0 (−7.2, −4.8)−7.4 (−8.5, −6.2)−11.1 (−12.3, −9.8)0.1133<0.0001
 Unweighted mean slope (% per year)−8.0 (−9.5, −6.4)−8.8 (−10.3, −7.2)−13.2 (−15.0, −11.4)0.4798<0.0001
1/Fasting insulin (pmol/L−1 × 10−3)
 n1,2551,2561,187
 Mean %change from 0 to 0.5 years25.7 (22.8, 28.7)13.5 (10.9, 16.2)−9.2 (−11.4, −7.0)<0.0001<0.0001
 Rate of change from 0.5 to 4 years (% per year)6.5 (5.8, 7.2)5.9 (5.2, 6.7)5.5 (4.7, 6.3)0.28980.0822
 Unweighted mean slope (% per year)6.9 (6.1, 7.8)5.3 (4.4, 6.3)5.2 (4.1, 6.2)0.01760.0128
  • For the log-transformed insulinogenic index and reciprocal fasting insulin, results are presented as a percentage change from baseline and mean rates of change (percent per year) ± 95% confidence limits. The unweighted mean rate of change (mean slopes) over 0.5 to 4 years are also listed. Changes from baseline, or rates of change, for which the 95% confidence limits do not bracket zero are statistically significantly different at the 0.05 level, without adjustment for multiple tests of significance.